Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, open-label, phase 1b/2, single-arm study evaluating safety and efficacy of anti-PD-1 monoclonal antibody (JS001) and nab-paclitaxel/gemcitabine for patients with advanced pancreatic adenocarcinoma

Next Previous
Trial Profile

A prospective, open-label, phase 1b/2, single-arm study evaluating safety and efficacy of anti-PD-1 monoclonal antibody (JS001) and nab-paclitaxel/gemcitabine for patients with advanced pancreatic adenocarcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Toripalimab (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 20 Jun 2020 New trial record
  • 31 May 2020 Interim results assessing safety and efficacy Gemcitabine, Paclitaxel and Toripalimab in previously untreated advanced PDAC patientspresented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top